eligibility_summary
Key eligibility: Adults ≥18, ECOG ≤2, life expectancy >12 mo, histologically confirmed DLBCL or FL grade 3B (incl. TIL/Richter, PMBCL, HGBCL-NOS), relapsed/refractory after ≥1 line, measurable disease, CD19+ and CD20+ tumor, willing to provide biopsy, adequate counts/organ function, contraception required. Exclude: prior loncastuximab, mosunetuzumab/CD20 bispecifics, allo-SCT, recent chemo/RT/CAR-T/ASCT/vaccines, active CNS lymphoma, uncontrolled illness/infections, significant cardiac/liver/autoimmune disease, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm trial in relapsed/refractory DLBCL tests two immunotherapies: 1) Loncastuximab tesirine (ADC): an anti‑CD19 monoclonal antibody linked to tesirine, a pyrrolobenzodiazepine (PBD) dimer cytotoxin that induces DNA interstrand crosslinks → apoptosis in CD19+ B cells. 2) Mosunetuzumab (bispecific T‑cell–engaging mAb): binds CD20 on B cells and CD3 on T cells to redirect/activate CD3+ T cells for targeted B‑cell killing. Targets: malignant B cells co‑expressing CD19 and CD20, effector CD3+ T cells are engaged. Key pathways: antigen-directed ADC cytotoxic delivery, T‑cell redirection/synapse formation, and DNA damage response.